Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer. 2018 Feb;26(2):539-48. doi: 10.1007/s00520-017-3863-9
Hauber AB, Mange B, Price MA, Wolin D, Bensink M, Kaye JA, Chandler D. Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey. Support Care Cancer. 2018 Jan;26(1):251-60. doi: 10.1007/s00520-017-3841-2
Marion S, Tzivelekis S, Darden C, Price MA, Sherif B, Garcia J, Kaye JA, Chandler D. "Same-day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer. 2016 Sep;24(9):3889-96. doi: 10.1007/s00520-016-3193-3
Smith RB, Bennett JE, Rantakokko P, Martinez D, Nieuwenhuijsen MJ, Toledano MB. The relationship between MX [3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone], routinely monitored trihalomethanes, and other characteristics in drinking water in a long-term survey. Environ Sci Technol. 2015 Jun 2;49(11):6485-93. doi: 10.1021/es5062006
Perez L, Medina-Ramon M, Kunzli N, Alastuey A, Pey J, Perez N, Garcia R, Tobias A, Querol X, Sunyer J. Size fractionate particulate matter, vehicle traffic, and case-specific daily mortality in Barcelona, Spain. Environ Sci Technol. 2009 Jul 1;43(13):4707-14. doi: 10.1021/es8031488
Poulos C, Whittington D. Time preferences for life-saving programs: evidence from six less developed countries. Environ Sci Technol. 2000 Apr 15;34(8):1445-55.